Opioid Addiction Treatment Co. Pulls $150M IPO
Braeburn Pharmaceuticals Inc., a commercial-stage biotech company developing a drug to treat opioid addiction, formally pulled an estimated $150 million initial public offering Wednesday, saying public markets are currently unattractive, echoing...To view the full article, register now.
Already a subscriber? Click here to view full article